State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Signal Transduct Target Ther. 2021 Feb 11;6(1):59. doi: 10.1038/s41392-020-00414-1.
It remains unknown for decades how some of the therapeutic fusion proteins positive in a small percentage of cancer cells account for patient outcome. Here, we report that osteosarcoma Rab22a-NeoF1 fusion protein, together with its binding partner PYK2, is sorted into exosomes by HSP90 via its KFERQ-like motif (RVLFLN). The exosomal Rab22a-NeoF1 fusion protein facilitates the pulmonary pre-metastatic niche formation by recruiting bone marrow-derived macrophages. The exosomal PYK2 activates RhoA in its negative recipient osteosarcoma cells and induces signal transducer and activator of transcription 3 activation in its recipient macrophages to increase M2 phenotype. Consequently, lung metastases of its recipient osteosarcoma cells are promoted by this exosomal Rab22a-NeoF1 fusion protein, and this event can be targeted by disrupting its interaction with PYK2 using a designed internalizing RGD peptide.
几十年来,人们一直不知道为什么一小部分癌细胞中的某些治疗性融合蛋白会影响患者的预后。在这里,我们报告骨肉瘤 Rab22a-NeoF1 融合蛋白与其结合伴侣 PYK2 通过其 HSP90 上的 KFERQ 样基序 (RVLFLN) 分选到外体中。外体中的 Rab22a-NeoF1 融合蛋白通过招募骨髓来源的巨噬细胞促进肺前转移龛形成。外体中的 PYK2 在其负接受的骨肉瘤细胞中激活 RhoA,并在其接受的巨噬细胞中诱导信号转导和转录激活因子 3 的激活,以增加 M2 表型。因此,其受体骨肉瘤细胞的肺转移被这种外体 Rab22a-NeoF1 融合蛋白所促进,而通过使用设计的内化 RGD 肽破坏其与 PYK2 的相互作用可以靶向该事件。